KDR and neoplasm: We also found a trend for highly vascularized tumors to be associated with worse prognosis, which is in line with the results of Zou et al. [14], and this further substantiates the recent and promising results of patients treated with apatinib, a small-molecule tyrosine kinase inhibitor that selectively binds to VEGFR2, decreasing tumor vascular density [24].